| 货号 | 产品名称 | 规格 | 库存 | 价格 | 数量 | 购买 |
|---|---|---|---|---|---|---|
| KR0194 | IL-35, Human, Recombinant | 10ug |
+
-
|
|
| 分子量 | 73.9 kDa |
|---|---|
| 表观分子量 | 90-120 kDa |
| 片段与标签 | Arg21-Lys229&Arg23-Ser219 C-6His |
| 生物活性 | Measured by its ability to bind biotinylated human IL6RB-Fch in a functional ELISA. |
| 物种 | Human |
| 表达宿主 | Human Cells |
产品特性
| 纯度 | ＞80% as determined by reducing SDS-PAGE. |
|---|---|
| 内毒素 | ＜1.0 EU per µg as determined by LAL test. |
| 保存 | Lyophilized Protein should be stored at ＜ -20℃, though stable at room temperature for 3 weeks.Reconstituted Protein solution can be stored at 4-7℃ for 2-7 days.Aliquots of reconstituted samples are stable at ＜ -20℃ for 3 months |
产品介绍
The novel Ebi3-IL-12alpha heterodimeric Cytokine has been designated Interleukin-35 (IL-35), is a member IL12 family Cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric Protein composed of IL-12α (P35) and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory Cytokine that may be specifically produced by T (reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4 (+)CD25 (+)Foxp3 (+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory Cytokine, along with TGFbeta Cytokine. IL-35 is a Cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory Cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.
